Adverse events that patients attribute to their drug treatment are generally considered to reduce adherence to medication. However, some patients interpret such symptoms as indicating drug effectiveness. If perceivedly effective drugs are more likely to be taken then adverse events may increase adherence. The extent to which patients interpret adverse events as indicating drug effectiveness is not well known. We investigated this in a cross-sectional questionnaire study of 1013 drug-treated hypertensive patients from 55 primary health-care centres and 11 internal medicine clinics in Sweden. We hypothesized that estimates of future risk of complications of hypertension made by hypertensive patients who had adverse events would be lower than estimates made by patients who did not have adverse events, and that these estimates would only differ when patients were estimating their risks in a setting where they continued taking antihypertensive drugs. Patients' risk estimates were measured with visual analogue scales and adverse events were detected by an open question. Contrary to our hypothesis, patients with adverse events (25.7%) gave higher estimates of future risk in the continuing medication setting. This association persisted in a multivariate analysis, where a number of factors related to adverse events and risk were controlled for (OR 1.76 (95% CI, 1.26-2.45), P ¼ 0.001 for the most highly correlated risk measure), but risk estimates did not differ between patients with and without adverse events in the setting of not continuing medication. Possible explanations for these findings are pre-existing differences in attitude towards drugs and level of fear of complications.
Introduction
Antihypertensive drug therapy aims to decrease hypertensive patients' cardiovascular risk while minimizing treatment-related inconveniences and side effects. 1 Side effects may be divided into adverse effects and adverse events on the basis of an assessment of causality. Thus, whereas an adverse effect is an adverse outcome that can be attributed to some action of a drug, an adverse event is an adverse outcome that coincides temporally with treatment but is not necessarily attributable to it. 2 Until a causality assessment has taken place, side effects reported by patients are best classified as adverse events. For the remainder of this text, adverse events will be used in the restricted sense of 'symptoms that patients attribute to their drug treatment'.
Nonadherence with medication is a major barrier to the achievement of potential treatment benefits. 3 The determinants of nonadherence with drugs are not well known, but patients with hypertension 4 and other diseases 5, 6 commonly state that they fail to follow treatment instructions because of adverse events. While it seems reasonable that adverse events decrease drug adherence, it is also conceivable that their impact on adherence is beneficial. This would occur if the following two conditions were true: (1) adverse events are interpreted by patients as an indication that the medication is effective, and (2) drugs perceived as effective are more likely to be taken.
The first condition finds some support from three qualitative studies, where interviewed patients were found to associate their drugs' curative power with the occurrence of adverse events. [6] [7] [8] Lorish et al 6 reported that 33% of patients with rheumatoid arthritis defined a 'powerful medication' as one that causes harmful adverse events; another 32% defined it as one that both causes harmful adverse events and leads to symptom control. 6 Leventhal et al 7 found that 10% of women with breast cancer gauged the effectiveness of their treatment in terms of the level of adverse events that they experienced. Fallsberg, 8 finally, investigated the understanding of adverse events among patients treated for asthma, hypertension and pain. She found that 31% of the views held by patients were consistent with a belief that desired and undesired effects of drugs exist in a 'natural balance'. 8 The second condition rests on the assumption that patients' drug-taking behaviour is in some way rational. Nonadherent behaviour falls into two broad categories: unintentional (eg, forgetting the drugs) and intentional. Social cognition models propose that intentional nonadherence is the outcome of a situation where the pros of being adherent are outweighed by the cons against being adherent.
9 If this model of human behaviour holds true, the net effect of adverse events on drug adherence would be the result of weighing the benefits of taking a drug believed to be effective (the pros) against the disadvantages of having unpleasant and assumedly drug-related symptoms (the cons). An important determinant of the outcome of this weighing process would be the extent to which patients associate adverse events with drug effectiveness. To our knowledge, this has not been quantified among hypertensive patients.
This study investigates the relationship between adverse events and perceived drug effectiveness in a cross-sectional sample of 1013 patients who had been prescribed at least one antihypertensive drug for current use. We have previously reported that 25.7% of these patients experienced adverse events from their antihypertensive drugs and that doing so was associated with a number of demographical and disease-related factors. 10 We have also described these patients' assessment of future risk of cardiovascular complications with and without antihypertensive medication. 11 Based on the observations made in the qualitative studies outlined above, [6] [7] [8] we hypothesized that patients with adverse events would give lower estimates of future risk of complications of hypertension, compared with patients without adverse events. We also hypothesized that these estimates would only differ when patients were estimating their risks in a setting where they continued taking antihypertensive drugs.
Material and methods

Participants
The study protocol was in accordance with the Declaration of Helsinki and was approved by the relevant regional ethics committees. A sample of 1013 patients was recruited from 55 primary healthcare centres and 11 clinics of internal medicine in Sweden. The recruitment sites were randomly chosen from a list of all primary health-care centres and clinics of internal medicine in the country. Sites that declined participation were replaced with others randomly chosen from the list. Patients were eligible for participation if they came for a regular follow-up appointment for hypertension, had hypertension as their main diagnosis and had been prescribed at least one antihypertensive drug for current use. Eligible patients were approached prior to a follow-up appointment and a majority agreed to participate. The resulting sample of patients was representative of the population of Swedish hypertensive patients receiving health care with respect to level of care, geographical location, male/female ratio and average number of antihypertensive drugs per patient. 10 
Procedures
A nurse collected demographic information from the patient and the most recent data on medication and blood pressure from the patient's case notes. The nurse then demonstrated how to use a visual analogue scale and checked the patient's understanding by observing how a number of everyday questions were completed. If this test was satisfactory, the patient filled in the study questionnaire. This five-page questionnaire was a modification of an instrument designed to evaluate symptoms among hypertensive patients, 12 which had previously been validated in a sample of 92 patients from a similar setting. 10 The follow-up appointment took place after completion of the questionnaire. Finally, the patient's physician recorded additional information such as the presence of major risk factors.
Definition and measurement of variables
Major risk factors were a history of myocardial infarction, stroke, renal complications to hypertension, peripheral vascular disease, heart failure or left ventricular hypertrophy, as recorded by the physician. The number of major risk factors was limited to a maximum of four per patient.
Presence of adverse events was assessed by the question 'Does your present medication for high blood pressure cause you any inconvenience? (Yes/ No)' followed by the question 'If yes, what inconvenience do you feel?' Patients' descriptions were classified into 20 predefined symptom categories or classified as 'other'. The word inconvenience in the question was preferred to the word side effect as the former was more in line with actual patient usage. Knowledge of actual patient usage came from a previous study of patient-physician interactions at follow-up appointments for hypertension, 13 where we found that both parties tended to avoid the word side effect and that patients described undesirable drug effects mostly in terms of inconveniences or gave accounts of specific symptoms.
The patients' perception of future cardiovascular risks was assessed by the question 'How much do you believe you risk being affected by complications, shown below, of high blood pressure with medication for high blood pressure in the next 10 years?'. This question was followed by six horizontal visual analogue scales entitled 'Further increase in blood pressure', 'Kidney failure', 'Heart failure', 'Stroke', 'Myocardial infarction' and 'Death'. The scales were marked 'No risk of being affected ¼ 0%' at the left extreme, and 'Will be affected ¼ 100%' at the right extreme. The question 'How muchy' was then repeated with the words 'without medication' substituted for 'with medication', followed by the aforementioned six scales. As visual analogue scales yield non-numerical data, 14 we did not aggregate the measures into overall scores.
Statistical analysis
The number of study participants was established for a research hypothesis other than that in the present study 10 and no post hoc power analysis was carried out for the present analysis.
For bivariate analysis, the Pearson w 2 statistic was used for categorical variables, the two-tailed Student's t-test for normally distributed continuous data and the Mann-Whitney U test was used for non-normally distributed continuous data. The median test was used for between-group comparisons of visual analogue scale measurements, which were generally skewed. Owing to the exploratory nature of this study, no correction for multiple comparisons was performed.
The purpose of the multivariate analysis was to investigate any association between adverse events and perceived risk while controlling for variables known to be associated with adverse events. We had previously found that patients who gave affirmative replies to the adverse events question were younger, better educated, took more antihypertensive drugs, had higher diastolic blood pressures and more major risk factors for cardiovascular disease. 10 These variables were included together with the adverse event and future risk variables into a multiple logistic regression. This analysis needs one dependent variable that is binary. Since there were no assumptions of directionality (ie the logistic regression was not used for prediction), choosing a dependent variable was a matter of feasibility. The adverse events variable (yes/no reply) was entered as dependent. Age, number of antihypertensive drugs and diastolic blood pressure were entered as continuous independent variables. Education, presence of major risk factors and measures of perceived risk were entered as binary independent variables (at least vs less than high school education, at least one vs no major risk factors and above vs below the median score for each item on the visual analogue scale). Two separate analyses were performed: one for the measures of risk with medication and one for the measures of risk without medication. The variables known to be associated with adverse events were first entered en bloc, followed by forward stepwise regression on each new variable in turn. The criteria for entry and removal were P ¼ 0.05 and 0.10, respectively. Goodness-of-fit was estimated by the Hosmer and Lemeshow test. All statistical analyses were performed with SPSS for Windows 10.0.
Results
Among the 1013 patients, 565 (55.8%) were female and 448 (44.2%) male. The patients' mean age was 62.0 years (range 19-87, s.d. 11.4) and the mean duration of hypertension was 12.0 years (range 0-61, s.d. 10.2). A majority of 692 (68.3%) patients had secondary education only, whereas 306 (30.2%) had high-school or university education. The mean number of antihypertensive drugs was 1.6 (range 1-4) and the mean number of major risk factors was 0.2 (range 0-4). Primary health-care centres and clinics of internal medicine were responsible for 810 (80.0%) and 203 (20.0%) of the patients, respectively.
There were 744 (73.4%) negative and 260 (25.7%) affirmative answers to the adverse events question. Five patients did not answer and four replied that they did not know. These nine patients (six women and three men) were excluded from further analysis. Among the 260 affirmative replies, six did not specify the inconvenience. Of the remaining 254 affirmative replies, 165 specified one, 64 two and 25 three or more inconveniences (mean 1.5, range 1-7, total n ¼ 384). Of these 384 specified inconveniences, 322 (83.9%) fitted into the predefined symptom categories. The remaining 62 (16.1%) replies mainly described symptoms that were not accounted for in the predefined categories.
Among the 1004 responses available for the analysis of adverse events and perceived risk, 822 (81.9%) included answers for all 12 questions about risk. The number of missing answers ranged from 32 (3.2%) for 'further increase in blood pressure without medication' to 93 (9.3%) for 'death with medication' (Table 1) . Patients with at least highschool education were more likely to reply to all 12 questions (87.1 vs 79.5%, P ¼ 0.004), as were younger patients (mean age 61.1 vs 66.3 years, Po0.001); no significant differences were found for presence of at least one major risk factor (P ¼ 0.11), presence of adverse events (P ¼ 0.13), number of antihypertensive drugs (P ¼ 0.40) or diastolic blood pressure (P ¼ 0.91).
In the bivariate analysis, associations were found between answering 'yes' to the adverse events question and higher estimates of all 10-year risks with medication (Po0.001-0.021). No associations were found for the estimates of risk without medication (P ¼ 0.16-0.93) ( Table 1) . Scatter plots of all with-medication risk estimates showed high degrees of intercorrelation. In the multivariate analysis of risks with medication, presence of adverse events was associated with the previously identified variables as well as with the risk estimate that was most strongly associated with adverse events in the bivariate analysis, that is, the estimate of 10-year risk of stroke (OR 1.76 (95% CI, 1.26-2.45), P ¼ 0.001). The goodness-of-fit measure (Hosmer and Lemeshow test) indicated that the statistical model fitted the data well (Table 2) . No association was found in the multivariate analysis of risks without medication.
Discussion
Contrary to our hypothesis, we found that experiencing adverse events was associated with higher estimates of future cardiovascular risk. This association only occurred when patients were considering what their risks would be in a scenario of continuing on antihypertensive drugs. The association was independent of a number of factors that had previously been identified as having a relationship with adverse events. The ratings for the six different complications were highly intercorrelated and only one of these, that is, the perceived 10-year risk of stroke, was associated with adverse events in the multivariate analysis. The question of drug-caused inconveniences yielded information about perceived symptoms in a large majority of cases, so we considered it a valid measure of adverse events.
The strength of this study was that it evaluated a reasonably large sample of patients that was representative of the Swedish hypertensive population in contact with health care. To our knowledge, the association between adverse events and perceived drug effectiveness has not previously been studied in a similar population.
One major weakness of the study was that we did not measure the actual impact of adverse events on medication adherence. Instead, we were limited to The fact that our results were not in line with findings from qualitative studies 6-8 may reflect differences in scope and methodology: we investigated associations on a group level but our hypothesis was based on findings from studies that focused on what meaning individual patients attach to adverse events. One reason for the incongruous findings may be that 'adverse events' meant different things in the two settings: our study may have picked up mostly minor symptoms, whereas patients in the interview studies may have referred to symptoms of a certain magnitude. It is also possible that adverse events are in fact interpreted by most patients as a sign of the medication being ineffective, but that this view was less explicit and therefore went undetected in the qualitative studies. Lastly, the interview data mostly concerned patients' views of adverse events and treatment effect in settings other than hypertension care and the results may not be transferable.
In trying to interpret our findings, one must search for underlying factors that may have caused the association between having adverse events and making a higher estimate of risk. Such underlying factors must account for the specificity of the association to the setting of continuing on antihypertensive drugs. One possible factor is the preexisting attitude towards medication. Patients who dislike drugs may be prone to blame these for various symptoms and to have less confidence in their effect. Another possible factor is the fear of hypertension-related complications. Patients who are more afraid of future complications may rate their risk higher and also be more likely to take their drugs despite unpleasant side effects.
This exploratory study has highlighted a number of uncertainties that surround the relationship between adverse events and perceived drug effectiveness. Since these two factors are likely determinants of medication adherence, studies designed to investigate their interdependence as well as their actual impact on adherence are warranted. A combination of qualitative and quantitative methods may ultimately enable us to answer questions like 'is there a level of adverse events that is optimal for adherence?'
